Eckert & Ziegler BEBIG Enters the US Market with its Ru-106 Eye Applicators
(Thomson Reuters ONE) -
Seneffe - Belgium, March 5, 2012. Eckert & Ziegler BEBIG (Euronext: EZBG;
Reuters: EZBG.BR; Bloomberg: EZBG: BB) has just announced the launch of its
Ruthenium-106 Eye Applicators on the US market, which will give physicians and
eye cancer patients access to a treatment option that preserves vision.
Eckert & Ziegler BEBIG is a global specialist in brachytherapy, a form of
radiotherapy in which cancer is treated by irradiation from a short distance.
The company is the exclusive worldwide manufacturer of Ru-106 Eye Applicators
(plaques) that treats uveal melanoma and retinoblastoma.
Both uveal melanoma and retinoblastoma can be fatal, if not diagnosed and
treated promptly. Retinoblastoma is an eye cancer of childhood with fatality
rates between 5 and 70%, depending on the geographic location. Uveal melanoma
shows a peak incidence at 55 years of age. Long-term fatality rates slightly
exceed 50% worldwide. The incidence of eye cancers worldwide is approximately
15,000 cases every year. According to the American Cancer Society, more than
2,300 patients in the US are diagnosed with eye cancer annually.
For more than 30 years, the unique features of Eckert & Ziegler BEBIG's Ru-106
Eye Applicators have been saving lives all over the world. Plaque brachytherapy
is a widely-used treatment option for many tumor stages, delivering a highly
concentrated radiation dose to the tumor while protecting surrounding healthy
tissues.
Ru-106 Eye Applicators are available in 16 different types for individual
treatment. The plaques consist of a thin film of Ru-106, a beta emitter,
encapsulated within pure silver sheets, with a total thickness of only 1 mm.
This allows comfortable handling for the ophthalmologist. With a half-life of
374 days, the Ru-106 the Eye Applicators have a long lifetime and can be used
multiple times within one year, allowing cost efficient procedures.
"We are very pleased that our Ru-106 Eye Applicators, which have an excellent
safety profile and proven efficacy, will be available for the treatment of eye
cancer patients in the US. The market introduction of our ophthalmic plaques is
a meaningful opportunity for us to contribute to the patient-centered care in
the US. Our ambition is to continuously expand our activities in this very
important market with further well-proven and innovative brachytherapy
solutions," commented Abel Luzuriaga, Managing Director of Eckert & Ziegler
BEBIG.
Customers who are interested in further information may
contactcustomer.support(at)bebig.eu directly.
Eckert & Ziegler BEBIG
...Contributing to saving lives!
Eckert & Ziegler BEBIG is a European-based group, active in the medical device
sector of the healthcare industry.
Its core business is the treatment of cancer by brachytherapy, a special form of
radiotherapy. Eckert & Ziegler BEBIG is a leader in brachytherapy in Europe and
is headquartered in Belgium. It has a production facility in Germany and
subsidiaries throughout Europe, as well as in India. Eckert & Ziegler BEBIG has
also established a worldwide network of distributors and agents to support its
product line.
The company's products and equipment are intended for use by oncologists,
radiologists, urologists and medical physicists.
Eckert & Ziegler BEBIG employs more than 150 people. It has been listed on the
Euronext stock exchange since April 1997 (Euronext: EZBG; Reuters: EZBG.BR;
Bloomberg: EZBG: BB).
Contact:
Claudia Mihlan
Head of Marketing
Paul-Emmanuel Goethals
Karolin Riehle
Investor Relations
Tel.: +32 (0) 64 520 808
E-mail:ir(at)bebig.eu
www.bebig.eu
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Eckert & Ziegler BEBIG via Thomson Reuters ONE
[HUG#1591017]
Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: hugin
" alt="Mindoro releases 2011 Financial Results and to Exhibit at PDAC 2012Datum: 05.03.2012 - 07:45 Uhr
Sprache: Deutsch
News-ID 121338
Anzahl Zeichen: 4593
contact information:
Town:
Seneffe
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 290 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Eckert & Ziegler BEBIG Enters the US Market with its Ru-106 Eye Applicators"
steht unter der journalistisch-redaktionellen Verantwortung von
Eckert & Ziegler BEBIG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
